20/20 Global Announces It Has Applied for a Name and Stock Symbol Change with FINRA
20/20 Global, Inc. (OTC Pink: TWGL) announced its application to FINRA for a corporate name change to Mycotopia Therapies Inc., along with a stock symbol change to MYCO. The firm aims to enhance its brand identity in the psychedelic therapy sector, focusing on treating mental health issues such as anxiety and depression. Additionally, the company is pursuing DTC eligibility to facilitate electronic share transfer for U.S. investors. Current shareholders are not required to take action in response to these changes.
- Name change to Mycotopia Therapies Inc. aligns with strategic transition into psychedelics.
- Pursuing DTC eligibility for easier electronic settlement of shares improves accessibility for investors.
- None.
MIAMI, Feb. 08, 2021 (GLOBE NEWSWIRE) -- 20/20 Global, Inc., (OTC Pink: TWGL) “Mycotopia”, a company focused on psychedelic therapies, announced today that it has applied to the Financial Industry Regulatory Authority ("FINRA") to change the name of the Company to Mycotopia Therapies Inc. The Company has also submitted an application to FINRA to change its stock symbol on OTC Market, requested symbol (MYCO).
The Company is also working to secure DTC eligibility by The Depository Trust Company ("DTC") for electronic settlement and transfer of its common shares in the United States. There is no action required by current shareholders in connection with any of these changes.
"Our name and symbol change are both in line with our strategic transition into the emerging field of psychedelics,” said 20/20 Global CEO, Ben Kaplan. "We believe it is in the best interest of our shareholders to rebrand our company to reflect our goal of providing psychedelic therapies through technology-focused, data-driven, and medical-based solutions for people dealing with anxiety, depression, bipolar disorders, PTSD, ADHD, autism, and addictions."
The Company's website is available at https://www.mycotopiatherapies.com.
About 20/20 Global and Mycotopia Therapy
Mycotopia Therapies Inc. provides psychedelic therapies through technology-focused, data-driven, and medical-based solutions for people dealing with anxiety, depression, bipolar disorders, PTSD, ADHD, autism, and addictions. With a primary focus of helping you heal and reclaim your life, Mycotopia Therapy endeavors to guide individuals through their journey of healing. This is accomplished by acquiring an understanding of the causes and works to mental wellness through psychedelic enhanced psychotherapy, integrated with a professional team of mental wellness practitioners and cutting-edge technology. Psychedelic therapy is a holistic and spiritual approach providing healing and has shown successful treatment for many years. The company operates as a subsidiary of EHAVE, Inc. (EHVVF). Additional information on Mycotopia Therapy can be found on the Company’s website at: https://www.mycotopiatherapies.com.
Forward-Looking Statement Disclaimer
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in 20/20 Global, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website, http://www.sec.gov.
Contact for 20/20 Global and Ehave
Investor Relations and Media Inquiries: Gabe Rodriguez
Email: erelationsgroup@gmail.com
Phone: (623) 261-9046
FAQ
What is the new name of 20/20 Global?
What is the new stock symbol for TWGL?
What is the focus of Mycotopia Therapies Inc.?
Do current shareholders need to take action regarding the name and symbol change?
